Bilive^® is：

The first domestically developed combined hepatitis A and hepatitis B vaccine in China and the second such vaccine globally. It remains the only combined hepatitis A and hepatitis B vaccine currently available in China.

Production process of bulk for hepatitis A vaccine is prequalified by the World Health Organization.

• Dual Protection in One Shot

An Important Contribution to Accelerate Hepatitis Elimination in China by 2030

• Convenience to prevent both diseases with lower cost

Providing simultaneous protection against both diseases and reducing the total number of required vaccinations to improve vaccination compliance

• Flexibility with vaccination doses for different needs

One dose for booster, two doses for immunity, three doses for comprehensive protection